Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a RET Fusion–Positive NSCLC Real-World Cohort: A Brief Report Authors: Alvaro Guimaraes Paula, Ximeng Liu, Amirali Karimi, Kyle Concannon, Simon Heeke, Yasir Y. Elamin, Kaiwen Wang, Jenny V. Pozadzides, Natalie Vokes, Janet Tu, Anne Tsao, Marcelo V. Negrao, Jianjun Zhang, Eric K. Singhi, Bingman Zhang, Waree Rinsurongkawong, Isadora Guimaraes Martins, Hai T. Tran, Don L. Gibbons, Monique B. Nilsson, John V. Heymach Published: 2026 ABSTRACT IntroductionRET fusion–driven NSCLC accounts for 2% of advanced lung adenocarcinomas, and selective RET tyrosine kinase inhibitors (RETis) are the current first-line standard-of-care treatment. However, acquired resistance to RETi can arise, and improved therapies for RETi-resistant tumors are needed.MethodsThis real-world retrospective cohort evaluated the outcomes of the combinations of chemotherapy with RETi (chemo/RETi) and chemotherapy with immunotherapy (chemo/IO) in patients with NSCLC who experienced progression while receiving RETi. For both groups, we assessed the overall response rate, using the Response Evaluation Criteria in Solid Tumors version 1.1; estimated progression-free survival (PFS) and overall survival using the Kaplan-Meier method; described the genomic features potentially related to RETi resistance; and analyzed safety data using the Common Terminology Criteria for Adverse Events version 5.0.ResultsOverall, 12 patients were included. The median PFS was 7.8 months for patients receiving chemo/RETi (n = 8) versus 3.5 months for patients receiving chemo/IO (n = 4); hazard ratio for progression or death was 0.24 (95% confidence interval: 0.07–0.83; p = 0.0063). The overall response rate was 38% in the chemo/RETi group and 25% in the chemo/IO group; one metabolic complete response was observed in the chemo/RETi group. Overall survival did not differ significantly between groups. Although chemo/RETi demonstrated improved outcomes, it was associated with more grade 3 treatment-related adverse events, including anemia, febrile neutropenia, and thrombocytopenia, compared with chemo/IO.ConclusionsOur data support the potential efficacy of chemo/RETi after progression on RETi, with significantly better PFS than chemo/IO, albeit with higher rates of hematologic toxicities. Introduction Activating fusions involving the tyrosine kinase domain of RET constitute an oncogenic driver in solid tumors, including lung cancer. RET fusion–positive NSCLC accounts for approximately 2% of all advanced NSCLC.1 The development of selective RET inhibitors (RETis), such as pralsetinib and selpercatinib, has revolutionized the treatment of these clinical cases, and RETis are broadly considered the first-line standard-of-care treatment. The ARROW2 and LIBRETTO-0013 trials demonstrated that RETis yield robust and durable responses: pralsetinib and selpercatinib had response rates of 61% and 64%, respectively, in patients with advanced NSCLC previously treated with platinum and 70% and 82%, respectively, in systemic treatment-naive patients. The progression-free survival (PFS) of patients treated with pralsetinib4 and selpercatinib5 was 13.0 and 26.2 months, respectively, in patients previously treated with platinum-based chemotherapy and 16.5 and 22.0 months, respectively, in treatment-naive patients. These two RETis have outperformed chemotherapy, immunotherapy, chemoimmunotherapy, and multi-target tyrosine kinase inhibitors (TKIs).6 Although these compounds have become the first-line standard of care, acquired resistance can still arise through on-target resistance mechanisms (e.g., secondary RET mutations) and off-target bypass mechanisms (e.g., MAPK-activating alterations in RAS, BRAF, MET, and FGFR genes).7,8 Although next-generation RETis are being studied to overcome on-target resistance,9 improvements in sequential therapies using currently approved regimens are still needed to overcome the more frequent off-target mechanisms of RETi resistance. We, therefore, retrospectively evaluated two different strategies for efficacy and safety following progression in patients receiving RETi: chemotherapy plus the current RETi therapy (chemo/RETi) and, alternatively, chemotherapy plus immunotherapy (chemo/IO). Here, in a real-world analysis of clinical outcomes of patients after progression on RETi, we report that chemo/RETi demonstrated improved outcomes compared with chemo/IO, although chemo/RETi was associated with more grade 3 adverse events. These data highlight the potential efficacy of chemo/RETi after progression on RETi in patients with a favorable performance status. Materials and Methods The Genomic Marker–guided Therapy Initiative (GEMINI) database at The University of Texas MD Anderson Cancer Center was used to identify patients with RET fusion–positive NSCLC treated between July 2018 and December 2025. Patients were included if (1) their RET fusion status was confirmed through fluorescence in situ hybridization, next-generation DNA sequencing, or RNA sequencing; (2) they received a single-agent RETi treatment, selpercatinib, pralsetinib, or both, for advanced disease and experienced progression while receiving that therapy; and (3) they received chemo/RETi or chemo/IO after that progression. Patients were then divided into two groups according to the therapy they received after that progression: chemo/RETi or chemo/IO. We retrospectively collected patients’ demographic, clinical, and genomic data from the electronic medical record. Treatment histories were analyzed alongside, and imaging-based responses were assessed using the Response Evaluation Criteria in Solid Tumors version 1.1. PFS and OS were estimated using the Kaplan-Meier method. The log-rank test was used to calculate the hazard ratio (95% confidence interval [CI]), and a p value less than 0.05 was considered significant. The Common Terminology Criteria for Adverse Events version 5.0 was used to record adverse events in both treatment groups. The study was approved by the MD Anderson Institutional Review Board, and all patients provided written informed consent. Results Patients We identified 106 patients with RET fusion–positive NSCLC at MDACC, of whom 64 had received selective RETi therapy. Among these, 45 experienced disease progression while on RETi. Ultimately, 12 patients who experienced progression while receiving RETi and then received either chemo/RETi or chemo/IO were included (Supplementary Fig. 1). The remaining 33 patients who progressed on RETi monotherapy were not included for the following reasons: 24 died due to cancer progression; four were lost to follow-up due to transitioning their care locally; two were enrolled in clinical trials (EP-0031 and LOXO-260); one received pemetrexed without additional agents; and one developed a secondary BRAF alteration and was treated with an RETi in combination with an MEK inhibitor. Patient demographics are listed in Supplementary Table 1. The median age was 56 (range, 32–77) years in the chemo/RETi group and 64 (range, 61–68) years in the chemo/IO group. All eight patients (100%) in the chemo/RETi group and three patients (75%) in the chemo/IO group received selpercatinib as RETi therapy; one patient in the chemo/IO group received selpercatinib and was switched to pralsetinib due to a grade 3 skin rash and Raynaud’s phenomenon. All patients in both groups received more than or equal to 2 cycles of doublet chemotherapy. In addition, five patients (62%) in the chemo/RETi group and three patients (75%) in the chemo/IO group completed at least four cycles of chemotherapy. Regarding chemotherapy regimen, all patients in the chemo/RETi group (100%) and two patients (50%) in the chemo/IO group received platinum/pemetrexed, and two patients (50%) in the chemo/IO group received platinum/taxane. All patients in the chemo/IO group and five patients (62%) in the chemo/RETi group had received RETi monotherapy as first-line treatment; the other three patients (38%) in the chemo/RETi group had received single-agent RETi as second-line or later treatment. Regarding metastatic sites, central nervous system (CNS) involvement was observed in two of eight patients (25%) in the chemo/RETi group and one of four patients (25%) in the chemo/IO group. Liver metastases were present in three of eight patients (38%) in the chemo/RETi group and in one of four patients (25%) in the chemo/IO group. Clinical Outcomes and Genomic Features The overall response rate was 38% for the chemo/RETi group, with three patients achieving a partial response, including one metabolic complete response, four patients (50%) with stable disease, including three with tumor shrinkage, and one patient having disease progression. In the chemo/IO group, one patient achieved a partial response (25%), two patients had stable disease (50%), and the last one had disease progression (Fig. 1A–E and Supplementary Table 2). Individual data for each patient are summarized in Table 1, including outcomes. As of December 2025, all patients in the chemo/IO group experienced progression, whereas in the chemo/RETi group, seven patients experienced progression and one patient had a partial response but discontinued selpercatinib due to an adverse event and was kept on pemetrexed (Fig. 1F).Figure 1(A) Waterfall plot revealing best confirmed tumor response to chemo/RETi or chemo/IO. The dotted horizontal lines illustrate the −30% threshold for partial response or +20% threshold for progression of disease. PET-CT imaging of patient 2 taken before (B, C) and after (D, E) initial treatment with chemo/RETi revealing complete metabolic response. The arrows indicate the target lesion. (F) Swimmer plot revealing the time to response and response duration for all the patients who received chemo/RETi (blue bar) and chemo/IO (red bar) after experiencing progression while receiving single-agent RETi in previous line (gray bar). AE, adverse event; PD, progression of disease; PR, partial response; SD, stable disease.Table 1Clinical Characteristics and Outcomes for Chemo/RETi or Chemo/IO PatientsPatientRegimenNumber of Chemo CyclesBest ResponseDuration on Chemo-Based TreatmentaDuration on Previous RET TKI MonotherapyaMetastatic Sites at Baseline1Carboplatin + Pemetrexed + Selpercatinib4SD (−13%)7.621.0CNS, bones2Carboplatin + Pemetrexed + Selpercatinib4PR (−43%)15.87.0Liver, lymph nodes3Carboplatin + Pemetrexed + Selpercatinib2SD (0)5.667.0Liver, lymph nodes4Carboplatin + Pemetrexed + Selpercatinib3SD (−17%)5.419.2Pleura, bones, lymph nodes5Carboplatin + Pemetrexed + Selpercatinib4PR (−44%)8.120.3Liver, pleura6Carboplatin + Pemetrexed + Selpercatinib4SD (−16%)9.831.0Lymph nodes7Carboplatin + Pemetrexed + Selpercatinib2PD (+62%)1.42.7Bones8Carboplatin + Pemetrexed + Selpercatinib6PR (−50%)10.112.7CNS, bones, lymph nodes9Carboplatin + Pemetrexed + Pembrolizumab4SD (−6%)3.510.9CNS, pleura, lymph nodes10Carboplatin + Paclitaxel + Pembrolizumab5PR (−48%)3.62.8Liver, bones, peritoneum, lymph nodes11Carboplatin + Pemetrexed + Pembrolizumab6SD (−17%)4.414.0Thyroid12Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab2PD (+40%)1.818.0Boneschemo, chemotherapy; CNS, central nervous system; IO, immunotherapy; PD, progression of disease; PR, partial response; SD, stable disease.aMeasured in months. (A) Waterfall plot revealing best confirmed tumor response to chemo/RETi or chemo/IO. The dotted horizontal lines illustrate the −30% threshold for partial response or +20% threshold for progression of disease. PET-CT imaging of patient 2 taken before (B, C) and after (D, E) initial treatment with chemo/RETi revealing complete metabolic response. The arrows indicate the target lesion. (F) Swimmer plot revealing the time to response and response duration for all the patients who received chemo/RETi (blue bar) and chemo/IO (red bar) after experiencing progression while receiving single-agent RETi in previous line (gray bar). AE, adverse event; PD, progression of disease; PR, partial response; SD, stable disease. Table 1Clinical Characteristics and Outcomes for Chemo/RETi or Chemo/IO PatientsPatientRegimenNumber of Chemo CyclesBest ResponseDuration on Chemo-Based TreatmentaDuration on Previous RET TKI MonotherapyaMetastatic Sites at Baseline1Carboplatin + Pemetrexed + Selpercatinib4SD (−13%)7.621.0CNS, bones2Carboplatin + Pemetrexed + Selpercatinib4PR (−43%)15.87.0Liver, lymph nodes3Carboplatin + Pemetrexed + Selpercatinib2SD (0)5.667.0Liver, lymph nodes4Carboplatin + Pemetrexed + Selpercatinib3SD (−17%)5.419.2Pleura, bones, lymph nodes5Carboplatin + Pemetrexed + Selpercatinib4PR (−44%)8.120.3Liver, pleura6Carboplatin + Pemetrexed + Selpercatinib4SD (−16%)9.831.0Lymph nodes7Carboplatin + Pemetrexed + Selpercatinib2PD (+62%)1.42.7Bones8Carboplatin + Pemetrexed + Selpercatinib6PR (−50%)10.112.7CNS, bones, lymph nodes9Carboplatin + Pemetrexed + Pembrolizumab4SD (−6%)3.510.9CNS, pleura, lymph nodes10Carboplatin + Paclitaxel + Pembrolizumab5PR (−48%)3.62.8Liver, bones, peritoneum, lymph nodes11Carboplatin + Pemetrexed + Pembrolizumab6SD (−17%)4.414.0Thyroid12Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab2PD (+40%)1.818.0Boneschemo, chemotherapy; CNS, central nervous system; IO, immunotherapy; PD, progression of disease; PR, partial response; SD, stable disease.aMeasured in months. Clinical Characteristics and Outcomes for Chemo/RETi or Chemo/IO Patients chemo, chemotherapy; CNS, central nervous system; IO, immunotherapy; PD, progression of disease; PR, partial response; SD, stable disease. Measured in months. The median PFS was 7.8 months for the chemo/RETi group and 3.5 months for the chemo/IO group (hazard ratio for progression or death = 0.24, 95% CI: 0.07–0.83, p = 0.0063; Fig. 2). There was a modest but nonsignificant OS benefit for the chemo/RETi group (median OS = 14.1 mo) versus the chemo/IO group (estimated median OS = 12.6 mo; Supplementary Fig. 2).Figure 2Kaplan-Meier curve of median progression-free survival in the analysis population for patients who received chemo/RETi (blue) and chemo/IO (red). Chemo, chemotherapy; IO, immunotherapy; PFS, progression-free survival; RETi, selective RET inhibitor. Kaplan-Meier curve of median progression-free survival in the analysis population for patients who received chemo/RETi (blue) and chemo/IO (red). Chemo, chemotherapy; IO, immunotherapy; PFS, progression-free survival; RETi, selective RET inhibitor. All patients underwent molecular profile testing (by tissue or liquid biopsy) immediately preceding chemo/RETi or chemo/IO treatment (Supplementary Fig. 3). No secondary RET mutations were found in either treatment group. However, we identified a new KRAS amplification in one patient in the chemo/RETi group and a new MET amplification in one patient in the chemo/IO group as potential contributors to RETi monotherapy resistance. Three patients in each group harbored a TP53 mutation, corresponding to 38% in the chemo/RETi group and 75% in the chemo/IO group. Safety We tracked patients’ treatment-related adverse events from the start of chemotherapy to RETi/IO progression and recorded grade 3 or higher events (Supplementary Table 3). No treatment-related deaths or grade 4 events were observed in either group. We identified 10 grade 3 events in the chemo/RETi group, involving six of the eight patients (75%), including three cases of febrile neutropenia (38%) and one case of grade 3 generalized edema (13%) that led to RETi discontinuation, although pemetrexed maintenance was continued. In the chemo/IO group, only one patient (25%) developed a grade 3 adverse event, febrile neutropenia. Discussion Clinical management of patients with NSCLC with tumors bearing RET fusions that have progressed on RETi is challenging. Here, we found that adding chemotherapy to the existing RETi on progression as a sequential treatment strategy significantly improved PFS compared with the current standard-of-care chemotherapy ± immunotherapy recommended by the National Comprehensive Cancer Network guidelines.10 Although this approach is not approved by the Food and Drug administration or other regulatory agencies, it has been adopted by some physicians in real-world practice, and we sought to report its outcome. The rationale includes the potential activity of RETis in tumor cells that retain the fusion, the avoidance of disease flare on TKI discontinuation, previously described in other oncogene-driven NSCLCs such as EGFR and ALK, the potential for improved intracranial control given the high CNS penetration of RETi, and the addition of chemotherapy to overcome off-target resistance mechanisms. In this sense, the study lays the foundation for a more definitive study, such as the COMPEL randomized phase II trial for EGFR-mutant NSCLC,11 in which the combination of osimertinib with chemotherapy had longer PFS and OS than chemotherapy alone in patients who had previously progressed on osimertinib. In a similar vein, the combination of chemotherapy with an ALK TKI had favorable outcomes compared with chemotherapy alone.12 To our knowledge, this is the first report to date evaluating the combination of RETi with chemotherapy in NSCLC. Still, these findings align with previous work. A retrospective cohort study of patients with RET fusion NSCLC treated with IO-based therapy, including chemo/IO regimens, found a median PFS of 4.4 and 4.2 months in patients treated in the first-line setting and in the second-line or later setting, respectively;13 these values are similar to the median PFS of 3.5 months in our study’s chemo/IO group. In addition, Negrao et al. found that tumors harboring RET fusion usually present with low or intermediate levels of PD-L1 and low tumor mutational burden, and that when such patients were treated with IO monotherapy, the median PFS was lower than 4 months.14 Another retrospective study, conducted in China in patients with RET fusion–positive NSCLC who received second-line chemotherapy-based treatment, reported a median PFS of 4.9 and 2.8 months for pemetrexed and non-pemetrexed regimens, respectively;15 both groups had a lower median PFS than that observed in the chemo/RETi group (7.8 mo) discussed here. The LIBRETTO-431 trial similarly demonstrated no added benefit from incorporating pembrolizumab into platinum-based chemotherapy in the first-line setting for patients with RET fusion–positive NSCLC, with comparable PFS of 11.2 months regardless of pembrolizumab use.16,17 Based on individual patient responses, outcomes with subsequent therapies do not appear to be consistently influenced by previous treatment. Notably, responses vary in both directions: some patients derive greater benefit from later-line combined therapy than from previous RETi monotherapy, whereas others experience the opposite. For instance, patient 2 had a shorter PFS on RETi monotherapy (7 mo), followed by a longer PFS with chemo/RETi (15.8 mo), whereas patient 3 had the reverse pattern, with prolonged benefit on RETi monotherapy (67 mo) and limited benefit with subsequent chemo/RETi (5.6 mo). The exact mechanism of resistance to single-agent RETi for each patient in our study was not fully understood. However, genomic profiling for all patients was performed after they experienced progression while receiving RETi monotherapy, and we identified a new KRAS amplification and MET amplification as potential bypass mechanisms of resistance to RETi. These data are supported by a study of selpercatinib-treated patients who underwent longitudinal genomic sequencing, which identified MAPK-activating alterations as the main mechanism of acquired resistance to selpercatinib, arising in seven of 18 patients.8 The presence of TP53 mutations, a marker of worse prognosis in ALK/RET/ROS1 rearranged NSCLC, may partly explain the limited efficacy observed with both chemo/RETi and chemo/IO therapies.18 However, individual patient-level data from the chemo/RETi group revealed responses in two of three patients with TP53 mutations, including one durable responder (patient 2). We also evaluated whether metastatic sites could account for differences in response. Given the small sample size, no definitive conclusions could be drawn. However, patients with CNS and liver metastases in the chemo/RETi group did demonstrate clinical benefit: patient 2 achieved a metabolic complete response in the liver, and patient 8 achieved a partial response with approximately 50% reduction in target lesions, deriving benefit from chemo/RETi for 10.1 months. Questions remain about the toxicity and ultimate benefit of chemo/RETi in NSCLC. A chemotherapy/TKI combination was previously found to be safe and effective in the proper context in the frontline FLAURA2 study: in EGFR-mutant NSCLC, the combination of osimertinib with chemotherapy yielded a better PFS than osimertinib alone.19 Although in our study patients treated with chemo/RETi had better PFS than those treated with chemo/IO, OS did not differ significantly between the groups. Furthermore, chemo/RETi raised concerns due to its higher incidence of grade 3 treatment-related adverse events, primarily hematologic toxicities. To alleviate these adverse effects, dose adjustments to chemotherapy, hemotransfusions, and granulocyte colony-stimulating factors were provided. In the chemo/RETi group, three patients (38%) had platinum permanently discontinued before 4 chemotherapy cycles were completed. Patients without disease progression continued RETi in combination with pemetrexed maintenance therapy. Limitations Limitations of our study include the limited number of cases from a single institution, the retrospective and real-world nature of these data, the imbalance of the two study groups, and the limited longitudinal sampling for mechanisms of acquired resistance to RETis. We, therefore, cannot draw definitive conclusions as to whether the addition of a RETi to chemotherapy improves efficacy. Conclusions Our data support chemo/RETi as a potentially effective strategy after progression in patients receiving RETi therapy, with improved PFS observed compared with chemo/IO, albeit with higher rates of grade 3 treatment-related AEs. CRediT Authorship Contribution Statement Alvaro Guimaraes Paula: Conceptualization, Methodology, Formal analysis, Investigation, Validation, Visualization, Writing - original draft, Writing - review & editing. Ximeng Liu: Formal analysis, Software, Investigation, Visualization, Writing - review & editing. Amirali Karimi: Formal analysis, Software, Investigation, Writing - review & editing. Kyle Concannon: Investigation, Writing - original draft, Writing - review and editing. Simon Heeke: Investigation, Writing - original draft, Writing - review and editing. Yasir Y. Elamin: Investigation, Formal analysis, Visualization, Writing - review & editing. Kaiwen Wang: Investigation, Formal analysis, Visualization, Writing - review & editing. Jenny Vu Pozadzides: Investigation, Formal analysis, Visualization, Writing - review & editing. Natalie Vokes: Investigation, Formal analysis, Visualization, Writing - review & editing. Janet Tu: Investigation, Formal analysis, Visualization, Writing - review & editing. Anne Tsao: Investigation, Formal analysis, Visualization, Writing - review & editing. Marcelo V. Negrao: Investigation, Formal analysis, Visualization, Writing - review & editing. Jianjun Zhang: Investigation, Formal analysis, Visualization, Writing - review & editing. Eric K. Singhi: Investigation, Formal analysis, Visualization, Writing - review & editing. Bingnan Zhang: Investigation, Formal analysis, Visualization, Writing - review & editing. Waree Rinsurongkawong: Investigation, Formal analysis, Visualization, Writing - review & editing. Isadora Guimaraes Martins: Investigation, Formal analysis, Visualization, Writing - review & editing. Hai T. Tran: Investigation, Formal analysis, Visualization, Writing - review & editing. Don L. Gibbons: Investigation, Formal analysis, Visualization, Writing - review & editing. Monique B. Nilsson: Investigation, Project administration, Resources, Methodology, Writing - review & editing. John V. Heymach: Conceptualization, Funding acquisition, Methodology, Resources, Project administration, Supervision, Writing - review & editing. Disclosure Dr. Guimaraes Paula reports receiving honoraria from Pfizer. Dr. Concannon reports receiving advisory board fees from Boehringer Ingelheim. Dr. Heeke reports receiving research support from Bristol Myers Squibb and Thermo Fisher; and receiving advisory board fees from Roche Diagnostics, Thermo Fisher, and Guardant Health. Dr. Elamin reports receiving research support from AstraZeneca, Spectrum, and Takeda; and receiving advisory board fees from AstraZeneca, Eli Lilly, Novartis, Spectrum, Sanofi, Takeda, Turning Point Therapeutics, Bristol Myers Squibb, Nuvation, Mirati, Merus, Taihoo, BluePrint Medicines, Catalyst Pharmaceuticals, and Kestrel Therapeutics. Dr. Wang reports receiving research support from MJH Life Sciences; and serving on the advisory board with Pfizer and Janssen. Dr. Vokes reports receiving research support from Mirati; and receiving advisory board fees from OncoCyte, Eli Lilly, Sanofi, Amgen, Xencor, AstraZeneca, Pfizer, Summit, OncoHost, Guardant, Regeneron, and Tempus. Dr. Tsao reports receiving research support from Merck, Genentech/Roche, Seagen, Millennium, Bristol Myers Squibb, Boehringer Ingelheim, Polaris, EMD Serono, and Takeda; and receiving advisory board fees from Novartis, Boehringer Ingelheim, Genentech/Roche, Eli Lilly, Bristol Myers Squibb, Epizyme, AstraZeneca/MedImmune, ARIAD, EMD Serono, Takeda, and Heron. Dr. Negrao reports receiving research support from Eli Lilly, Mirati, Bristol Myers Squibb, Novartis, Alaunos, AstraZeneca, Pfizer, Genentech, Navire, and Frontier Medicine; receiving advisory board fees from Genentech, Sanofi, Pfizer, Eli Lilly, AstraZeneca, and Bristol Myers Squibb; receiving honoraria from OncLive, Ideology, BIO Brasil, Medscape, DAVA Oncology, Targeted Oncology, ApotheCom, and Ashfield Healthcare; and receiving support for attending meetings from Ideology, DAVA Oncology, and Targeted Oncology. Dr. J. Zhang reports receiving research support from Merck, Johnson and Johnson, Novartis, Summit, and Helius; and receiving advisory board fees from Johnson and Johnson, AstraZeneca, Helius, Geneplus, OrigMed, Innovent, Varian, and Catalyst. Dr. Singhi reports receiving research support from Rexanna’s Foundation for Fighting Lung Cancer; and receiving advisory board fees from AstraZeneca, Novocure, Amgen, Janssen, Regeneron, Bristol Myers Squibb, Bayer, Boehringer Ingelheim, Eli Lilly, CARIS, and Nuvation Bio. Dr. B. Zhang reports receiving research support from Lung Cancer Research Foundation; receiving advisory board fees from Abdera Therapeutics, Daiichi Sankyo, and OncoHost; and receiving honoraria from IDEOlogy Health. Dr. Tran reports receiving advisory board fees from ABION. Dr. Gibbons reports receiving research support from Mirati, NGM Biopharmaceuticals, and Boehringer Ingelheim; receiving advisory board fees from Menarini Ricerche, Onconova, and Eli Lilly. Dr. Nilsson reports receiving royalties and licensing fees from Spectrum Pharmaceuticals. Dr. Heymach reports receiving all support for the present manuscript from The Happy Lungs Project, The Hamoui Foundation and LUNGevity, and The Ruth Leggett Distinguished Chair Endowment; receiving research support from AstraZeneca, Boehringer Ingelheim, Spectrum, Mirati, Bristol Myers Squibb, and Takeda; receiving royalties and licensing fees from Spectrum Pharmaceuticals; serving on the advisory board with Genentech, Mirati Therapeutics, Eli Lilly, Janssen Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Regeneron, Takeda Pharmaceuticals, BerGenBio, Jazz Pharmaceuticals, Curio Science, Novartis, AstraZeneca Pharmaceuticals, BioAlta, Sanofi, Spectrum Pharmaceuticals, GlaxoSmithKline, EMD Serono, BluePrint Medicine, and Chugai Pharmaceutical. The remaining authors declare no conflict of interest.